Repatha (Evolocumab) and Acetaminophen Interaction: Safety, Metabolism, and Clinical Guidance

Why These Two Drugs Raise the Interaction Question

Patients prescribed evolocumab for high-risk hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) frequently reach for acetaminophen to manage everyday aches, headaches, or injection-site discomfort. The question of safety arises because both drugs appear in the same FDA labeling context around hepatic effects. That overlap, though, does not mean the two interact at a metabolic level.

Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating PCSK9 protein. Its elimination occurs through receptor-mediated endocytosis and proteolytic catabolism, the same pathway the body uses to clear other endogenous immunoglobulins [1]. It does not pass through the liver's cytochrome P450 system. Acetaminophen, by contrast, is a small-molecule analgesic that relies heavily on hepatic conjugation (glucuronidation and sulfation) and, at higher doses, on CYP2E1-mediated oxidation to the reactive metabolite NAPQI [2]. Because these two agents use entirely different elimination routes, competition for the same enzyme or transporter does not occur.

No formal drug-drug interaction study between evolocumab and acetaminophen has been published in peer-reviewed literature, and the Repatha prescribing information does not list acetaminophen as a contraindicated or cautioned co-medication [1]. The absence of a listed interaction reflects sound pharmacologic reasoning, not an oversight.

Pharmacokinetic Profiles: No Overlapping Pathways

The reason a pharmacokinetic interaction is implausible comes down to molecular size and clearance biology. Evolocumab has a molecular weight of approximately 144 kDa. Drugs metabolized by cytochrome P450 enzymes are almost exclusively small molecules below 1 kDa [3].

Acetaminophen (151 Da) follows three primary metabolic routes in the liver. Roughly 52 to 57% undergoes glucuronidation via UGT1A1, UGT1A6, and UGT1A9. About 30 to 44% is sulfated by SULT1A1. A smaller fraction, approximately 5 to 10%, is oxidized by CYP2E1 and to a lesser extent CYP1A2 and CYP3A4 to form NAPQI [2]. NAPQI is then conjugated with glutathione and excreted. At therapeutic doses, glutathione reserves handle NAPQI production without difficulty. At supratherapeutic doses (above 4,000 mg/day in healthy adults), glutathione depletion leads to hepatocellular necrosis.

Evolocumab does not inhibit, induce, or serve as a substrate for any CYP isoform, UGT enzyme, or drug transporter (including P-glycoprotein, OATP1B1, or OATP1B3) [1]. In FOURIER (N=27,564), the largest completed cardiovascular outcomes trial for a PCSK9 inhibitor, concomitant medications including analgesics were permitted throughout the study period. No signal of enhanced hepatotoxicity emerged with any co-administered small molecule [4].

Hepatic Safety: Separate Risks, Not Compounding Ones

Both drugs carry hepatic-related safety information, but the mechanisms are distinct and do not amplify each other.

Acetaminophen hepatotoxicity is dose-dependent and well characterized. The FDA requires a boxed warning on prescription combination products containing acetaminophen, citing severe liver injury as the primary risk [5]. The threshold for concern in adults without liver disease is typically 4,000 mg per day, though many hepatologists recommend a 3,000 mg ceiling for patients with any hepatic risk factor, including regular alcohol use.

Evolocumab's hepatic profile is considerably milder. In pooled phase III data (OSLER-1 and OSLER-2, combined N=4,465), alanine aminotransferase (ALT) elevations exceeding three times the upper limit of normal occurred in 0.4% of evolocumab-treated patients versus 0.4% of standard-care patients [6]. That rate is indistinguishable from background. The Repatha label lists hepatic enzyme abnormality as an adverse reaction reported in post-marketing surveillance, but without a defined causal relationship [1].

A patient taking evolocumab 140 mg every two weeks and acetaminophen 1,000 mg as needed for pain is not layering two hepatotoxic agents. One drug rarely affects liver enzymes. The other only does so when its dose exceeds glutathione-buffering capacity. Standard dosing of both carries low hepatic risk.

What the Major DDI Databases Report

Clinicians and pharmacists routinely check commercial drug interaction databases before clearing a new combination. The evolocumab-acetaminophen pairing receives consistent classification across platforms.

Lexicomp assigns no interaction rating to this pair. Micromedex does not list a monograph for the combination. Clinical Pharmacology returns no interaction result. The absence of an entry is itself informative: these databases flag interactions down to theoretical CYP competition, and they find nothing to flag here [3].

The FDA Adverse Event Reporting System (FAERS) contains no signal of excess hepatic events in patients taking both drugs. A PubMed search for "evolocumab acetaminophen interaction" returns zero results as of May 2026. This consistent silence across pharmacovigilance systems, regulatory databases, and peer-reviewed literature supports the mechanistic expectation that no interaction exists.

Dose Guidance for Acetaminophen While on Evolocumab

Acetaminophen dosing does not require adjustment because a patient is receiving evolocumab. The same population-wide limits apply.

For adults without hepatic impairment, the maximum recommended dose is 4,000 mg per day, divided into doses of 325 to 1,000 mg every 4 to 6 hours [2]. The American College of Gastroenterology and multiple hepatology guidelines recommend reducing to 2,000 mg per day in patients with chronic liver disease or cirrhosis [7]. Patients consuming three or more alcoholic drinks daily should discuss acetaminophen use with their prescriber regardless of other medications.

Evolocumab dosing remains fixed: 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. No titration based on concomitant analgesic use is indicated [1]. Patients who experience injection-site reactions (reported in 5.7% of evolocumab-treated patients in FOURIER) may use acetaminophen 500 to 1,000 mg as a pre-treatment or post-injection comfort measure [4].

Monitoring Recommendations for Long-Term Co-Use

While routine therapeutic drug monitoring is not required for either agent in isolation, a reasonable hepatic surveillance plan provides reassurance for patients concerned about combining them.

A baseline comprehensive metabolic panel (CMP) that includes ALT, AST, and total bilirubin should be obtained before starting evolocumab. The 2018 AHA/ACC Cholesterol Guideline recommends checking a fasting lipid panel and safety labs within 4 to 12 weeks of initiating any new lipid-lowering therapy [8]. If liver enzymes remain within normal limits at that check, and acetaminophen use stays within recommended limits, no additional monitoring is required solely because the two drugs are co-administered.

Patients should be counseled to report these symptoms promptly: unexplained fatigue, right upper quadrant pain, dark urine, or jaundice. These warrant immediate ALT and AST measurement. The trigger for concern is not the drug combination itself but any deviation from expected acetaminophen dosing patterns, particularly accidental overdose from combination products containing hidden acetaminophen [5].

"Patients often don't realize that their cold medicine, sleep aid, and separate Tylenol bottle all contain acetaminophen," notes the FDA's 2011 safety communication. "The risk of liver damage increases when they inadvertently take multiple products at once" [5]. This warning applies to all patients, not specifically to those on evolocumab.

Other Repatha Drug Interactions Worth Knowing

While acetaminophen poses no interaction concern, patients on evolocumab should be aware of the broader drug interaction profile.

Statins are the most commonly co-prescribed drugs with PCSK9 inhibitors. In FOURIER, 69.3% of patients were on high-intensity statin therapy. No pharmacokinetic interaction was observed, and the LDL-C reduction was additive: evolocumab lowered LDL-C by 59% relative to placebo on top of statin therapy [4]. The combination is both expected and encouraged by guidelines [8].

Ezetimibe, another lipid-lowering agent, was used by 5.2% of FOURIER participants alongside evolocumab. Again, no interaction signal emerged [4]. Warfarin, a narrow-therapeutic-index drug metabolized by CYP2C9, has no known interaction with evolocumab. Because evolocumab does not interact with CYP enzymes, it does not alter the INR in warfarin-treated patients [1].

NSAIDs represent the analgesic class where hepatic and gastrointestinal monitoring is more clinically relevant, particularly in cardiovascular patients already on antiplatelet therapy. The American Heart Association has cautioned against chronic NSAID use in patients with established ASCVD due to increased thrombotic risk [9]. Acetaminophen is often the preferred analgesic in this population precisely because it avoids that cardiovascular signal.

Special Populations: When Extra Caution Applies

Three patient subgroups warrant additional attention when evolocumab and acetaminophen are used together, not because of a drug-drug interaction, but because of altered baseline hepatic physiology.

Patients with non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) carry higher baseline ALT values. An estimated 25% of adults with hypercholesterolemia also meet criteria for MASLD [10]. In these patients, evolocumab itself may actually provide benefit: PCSK9 inhibition has been associated with reduced hepatic fat content in preliminary studies, and LDL-C lowering can improve steatosis markers [10]. Acetaminophen should still be capped at 2,000 to 3,000 mg per day in this group as a general hepatic precaution.

Elderly patients (age 65 and older) show reduced glucuronidation capacity and lower glutathione reserves. The AGS Beers Criteria do not list acetaminophen as potentially inappropriate, but geriatric prescribing guidance recommends using the lowest effective dose [11]. Evolocumab pharmacokinetics are not meaningfully altered by age [1].

Patients with homozygous familial hypercholesterolemia (HoFH) receiving evolocumab 420 mg monthly showed a more modest LDL-C reduction (approximately 30%) compared to heterozygous FH patients, but hepatic safety remained consistent with the broader dataset [1]. No dose adjustment of acetaminophen is needed in HoFH.

Practical Counseling Points for Patients

Patients should hear three clear messages about this combination. First, evolocumab and acetaminophen do not interact. They travel completely different metabolic pathways. Second, acetaminophen's risks are independent of evolocumab and are entirely dose-related. Keeping total daily intake below 3,000 mg provides a comfortable safety margin. Third, the biggest acetaminophen danger is hidden sources. Patients should read labels on all over-the-counter products, including cold and flu remedies, sleep aids, and prescription opioid combinations, because each may contain 325 to 500 mg of acetaminophen per dose [5].

Patients experiencing frequent pain that requires daily acetaminophen use should discuss the underlying cause with their clinician rather than increasing the dose. A baseline hepatic panel and a 12-week follow-up CMP provide documentation that both drugs are well tolerated.